1. Clients participation must be voluntary and not coerced.
2. Clients must sign an Informed Consent that indicates and understanding of the risks and benefits of ibogaine administration.
3. Clients must undergo a general medical evaluation by a doctor who will provide a report.
4. If requested, clients must supply a copy of their medical history questionnaire (generally required upon the intake visit to a physician).
5. If requested, clients must respond to a Beck Depression Inventory questionnaire.
6. Clients must obtain an EKG (electrocardiogram) and report.
7. Blood tests including:
8. Clients must complete the ICS intake-form.
Note: There is a test that is an evaluation of cytochrome P450 enzymes activity. Particularly, P450 2D6 (CYP4502D6) plays a significant role in the metabolism of ibogaine to noribogaine, its active metabolite. The test determines whether the client will be a "poor metabolizer" (PM), "intermediate metabolizer (IM), extensive metabolizer (EM) or "ultra-rapid" metabolizer (UM). This testing is not required by ICS, but could be something useful determine how well you will benifit from the metabolite noribogaine.
1. Clients with a history of active neurological or psychiatric disorders, such as cerebellar dysfunction, psychosis, organic brain disease or dementia, that require treatment.
2. Clients who have a Beck Depression Inventory score greater than or equal to twenty-four.
3. Clients requiring concomitant medications that may cause adverse ibogaine/other drug interactions (e.g., antiepileptic drugs, antidepressants, neuroleptics, etc.)
4. Clients with a history of sensitivity or adverse reactions to the treatment medication.
5. Clients with a history of significant heart disease or a history of myocardial infarction.
6. Clients with blood pressure above 170 mm Hg systolic/105 mm Hg diastolic or below 80 mm Hg systolic/60 mm Hg diastolic or a pulse greater than 120 beats per minute or less than 50 beats per minute.
7. Clients who have a history of hypertension uncontrolled by conventional medical therapy.
8. Clients who have received any drug known to have a well-defined potential for toxicity to a major organ system within the month prior to entering the session.
9. Clients who have clinically significant laboratory values outside the limits thus specified by normal laboratory parameters.
10. Clients who have any disease of the gastrointestinal system, liver or kidneys, or abnormal condition which compromises a function of these systems and could result in a possibility of altered metabolism or excretion of ibogaine will be excluded. As it is not possible to enumerate the many conditions that might impair absorption, metabolism or excretion, the provider should be guided by evidence such as:
A. History of major gastrointestinal tract surgery (e.g., gastrectomy, gastrostomy, bowel resections., etc.) or a history or diagnosis of an active peptic ulcer or chronic disease of the gastrointestinal tract, (e.g. ulcerative colitis, regional enteritis, Crohn's disease or gastrointestinal bleeding).
B. An Indication of impaired liver function.
C. An indication of impaired renal function.
11. Patients with active tuberculosis.
Copyright 2012-2017 © Inukshuk Counselling Service. All rights reserved.